Impact of concomitant Methotrexate on efficacy, safety and adherence of Ustekinumab-treatment in patients with active Psoriatic Arthritis (MUST-Study)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Apr 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Apr 2023 Results of post-hoc analysis on 112 psoriatic arthritis serum samples of subjects treated with open-label Ustekinumab and either concomitant Methotrexate published in the Rheumatology
14 Nov 2022 Results of a sub-group analysis assessing differences in response rates to pain and ACR response between male and female and treatment groups (UST+MTX or UST only) using data from this trial presented at the ACR Convergence 2022
04 Jun 2022 Results of post-hoc analysis assessing the impact of concomitant methotrexate on ustekinumab-immunogenicity in patients with active psoriatic arthritis, presented at the 23rd Annual Congress of the European League Against Rheumatism.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com